Indolent lymphoma is a type of non-Hodgkin lymphoma that grows and spreads particularly slowly. Because of this, it may not cause any symptoms.
Non-Hodgkin lymphoma is a blood cancer that starts in the lymphatic system. The lymphatic system is part of the immune system. It includes the tissues and organs that carry infection-fighting white blood cells around the body.
In non-Hodgkin lymphoma (NHL), white blood cells start to multiply in an abnormal way and collect in parts of the lymphatic system, such as the lymph nodes.
The way NHLs grow is categorized in the following ways:
Sometimes, indolent lymphomas can become aggressive lymphomas.
This article will explain the prevalence of indolent lymphomas. It will list the different types and stages of the condition, its outlook, and symptoms a person with indolent lymphoma might experience. It will also describe the importance and different options of treatment.
About 40% of all people with NHL have indolent lymphoma.
In the United States, NHL accounts for around 4% of all cancers. The American Cancer Society estimates that as of 2021, NHL is diagnosed in around 81,560 people (including adults and children).
NHL can affect people of any age. It is more common after the age of 75. However, it is also one of the most common cancers among children, teens, and young adults.
White people are more likely than Black people to develop NHL. People assigned male at birth are more likely than people assigned female at birth to develop NHL.
The subtypes of indolent lymphoma include:
Follicular lymphoma (FL) usually occurs in multiple lymph nodes, as well as in the bone marrow. The average age at diagnosis of FL is 65 years.
FL is the most common lymphoma in the U.S. It is the most common type of indolent lymphoma. It makes up 35% of all NHLs and 70% of all indolent lymphomas.
FLs may respond well to treatment. However, it can be challenging to cure completely. Doctors may delay treatment until the FL starts causing symptoms.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are both indolent types of cancer. They may affect the blood, bone marrow, or lymph nodes.
CLL and SLL can cause different symptoms depending on where the tumors have formed. Symptoms are usually non-specific and generalized, including:
CLL and SLL may not cause any symptoms for several years, meaning treatment may not be immediately necessary. Treatment usually aims to manage the cancer rather than cure it.
Marginal zone lymphomas (MZL) account for around 510% of NHLs. They develop in a particular region at the edge of normal lymphoid tissues, called the marginal zone.
There are different subtypes of MZL, which arise in different areas of the lymphatic system.
Cutaneous T-cell lymphoma (CTCL) is rare. It develops in T-cells in the skin and can spread to lymph nodes, blood, and other organs. There are two subtypes:
Treatment will depend on the type and stage of CTCL.
These rare indolent lymphomas originate in B-lymphocyte cells and cause thickening of the blood. This can lead to headache, confusion, and visual blurring.
Waldenstrm macroglobulinemia can cause weakness as it causes the blood to thicken. It can increase a persons risk for blood clots or stroke.
Treatment only begins if symptoms develop. As this cancer advances, it can involve the lungs, gastrointestinal tract, and other organs.
To determine the extent of indolent lymphoma, a medical team will perform a series of tests. They will compare the results of the tests against a staging system to find out what stage the disease is at.
The stages are as follows:
However, the staging of NHL can vary depending on its type.
The cause of NHL, including indolent lymphoma, is unknown. However, research has revealed possible risk factors, including:
A person can live with indolent lymphoma for several years before showing any symptoms since it is slow-growing. A person may have fewer symptoms than a person with aggressive lymphoma. However, the symptoms may be similar.
The most common symptoms of NHL indolent lymphoma are:
Every persons NHL is different. Their outlook depends on the subtype of lymphoma they have, where it started, and how their body responds to treatment.
A 2020 study focused on follicular lymphoma, the most common type of indolent lymphoma. It highlighted the positive survival rate for this type of lymphoma, stating the 5-year overall survival rate was 92% for all participants in the study.
Researchers also highlighted the rapid advances in treatment that can impact this outlook and reiterated the importance of early diagnosis.
Learn about stage 4 lymphoma here.
Many people who eventually receive a diagnosis of NHL visit their doctor about a lump they have found that has not gone away. Sometimes lumps are found through routine check-ups.
If a doctor suspects lymphoma, they can order a series of tests, exams, and scans to confirm the diagnosis. These include:
The treatment for indolent lymphoma depends on the subtype of NHL being treated, the stage it is, and any other health conditions they may have.
All treatment plans will be planned by a team of healthcare professionals with expertise in treating lymphoma.
According to the National Cancer Institute, nine standard treatments are available:
Through clinical trials, researchers are investigating new treatments, including vaccine therapy. With ongoing research, treatment options are improving all the time.
Indolent NHL is not curable. However, it can respond very well to treatment. Some doctors will suggest people with indolent lymphoma wait to receive treatment until they show symptoms. This is safe as long as a person continues to undergo regular monitoring of the condition.
Untreated and unmonitored indolent lymphoma may develop into a more aggressive type.
After being treated for indolent NHL, some people may go on to experience long-term conditions. These include:
Indolent lymphoma is the term for a set of slow-spreading blood cancers with no known cause. They are a type of NHL. Some people with indolent lymphoma do not experience symptoms for several years.
Treatment may begin after symptoms have started to show. Until this time, it is important for a person to undergo monitoring for the condition or it may develop into a more aggressive type.
With early diagnosis and the appropriate treatment, a person can live with indolent lymphoma for many years.
See original here:
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021